[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cirrhosis-of-the-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cirrhosis-of-the-liver":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100643884","ultrasound-assessment-of-diaphragmatic-structure-and-function-in-patients-with-liver-cirrhosis-a-point-of-care-tool-for-predicting-complications-and-sarcopenia-in-limited-resource-settings-100643884",false,"NCT07667608","Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of liver cirrhosis based on clinical, biochemical, histological, or imaging criteria.\n3. Ability to provide written informed consent in Arabic or English.\n4. For Subgroup A: clinical indication for large-volume paracentesis with an ascitic volume of ≥5 liters.\n5. For Subgroup B: confirmed hepatic hydrothorax or confirmed absence of pleural effusion on ultrasound or chest X-ray.\n6. For Subgroup C: radiologically confirmed HCC by triphasic CT or MRI according to EASL\u002FAASLD diagnostic criteria, with available CT imaging for L3 SMI analysis.\n\nExclusion Criteria:\n\n1. Significant pre-existing primary pulmonary disease (e.g., moderate-to-severe COPD defined as FEV1\u002FFVC \\\u003C70% with FEV1 \\\u003C60% predicted, interstitial lung disease, pulmonary fibrosis) that independently affects diaphragmatic mechanics.\n2. Recent thoracic surgery, thoracocentesis within the preceding 72 hours, or thoracic trauma.\n3. Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome) independently affecting diaphragmatic function.\n4. Active mechanical ventilation at time of enrollment.\n5. Pregnancy.\n6. Inability to achieve adequate ultrasound acoustic windows (e.g., due to extreme obesity or surgical dressings).\n7. Contraindications to paracentesis in Subgroup A (e.g., disseminated intravascular coagulation, bowel obstruction).\n8. Prior or planned liver transplantation within the study period, which would confound longitudinal follow-up.\n9. Refusal or inability to provide informed consent.",true,"ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults. The study will measure diaphragmatic thickness, thickening fraction, and excursion using bedside ultrasound and compare these values between patients with cirrhosis and healthy volunteers. The main questions it aims to answer are:\n\nDo patients with cirrhosis show reduced diaphragmatic function compared to healthy adults?\n\nDoes removal of ascitic fluid by paracentesis improve diaphragmatic mechanics?\n\nCan ultrasound measurements of the diaphragm serve as a reliable non-invasive marker of sarcopenia when compared to CT scans?\n\nParticipants will:\n\nUndergo diaphragmatic ultrasound during quiet and deep breathing\n\nProvide clinical and laboratory data related to liver disease severity\n\nIn some cases, have ultrasound repeated before and after paracentesis\n\nFor patients with hepatocellular carcinoma, CT scans will be analyzed to measure muscle mass",[24,25,26,27,28,29],"Cirrhosis of the Liver","Ascites","Pleural Effusion Disorder","Hepatocellular Carcinoma (HCC)","Sarcopenia","Diaphragm Movement","NOT_YET_RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":20},"2026-08-10",{"date":38,"type":20},"2027-12-10",{"name":40,"class":41},"Assiut University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":58,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100566715","abbreviated-magnetic-resonance-imaging-vs-ultrasound-surveillance-for-liver-cancer-detection-in-people-at-high-risk-of-developing-liver-cancer-100566715","NCT06658782","Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer","AMULET","Inclusion Criteria:\n\n* • Participant is willing and able to give informed consent for participation in the study AND\n\n  * All genders, aged 18 years or above AND\n  * Eligible for HCC US surveillance in the opinion of the local investigators AND\n  * Child Pugh score A or B AND\n  * Diagnosed with liver cirrhosis due to ArLD, MASLD, chronic hepatitis C, chronic hepatitis B, genetic haemochromatosis AND\n  * Have an annual risk of HCC of at least 3% as determined by the aMAP score OR\n  * Participants with chronic liver disease (with or without cirrhosis) who had successful treatment for HCC, have not had a recurrence and have returned to 6 monthly surveillance with USS\n\nExclusion Criteria:\n\n* • Contraindication to MRI\n\n  * Known allergy \u002F reaction to intravenous gadolinium contrast\n  * Prisoners\n  * Pregnancy or breast feeding\n  * Previous liver transplant\n  * Participants who are known to have indeterminate liver nodules on prior imaging requiring ongoing follow-up with MRI or CT\n  * Previous HCC treated with curative intent and still being followed up with CT or MRI with contrast for possible recurrence\n  * Estimated glomerular filtration rate of \\\u003C30 ml\u002Fmin\u002F1.73m2\n  * Participant is on haemodialysis\n  * Participants who are unlikely to comply with the study procedures in the opinion of the local investigator\n  * In the view of the clinician, if the participant has a co-morbidity likely to lead to death within the following 12 months",{"count":50,"type":20},300,"Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.\n\nBackground: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer.\n\nComputed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound.\n\nDesign and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.",[53,54,55,56,24,57],"Cirrhosis","Cirrhosis Due to Hepatitis B","Cirrhosis and Chronic Liver Disease","Cirrhosis Due to Hepatitis C","Hepatocellular Carcinoma",[59,60,61,62],"SURVEILANCE","DIAGNOSTIC ACCURACY","abbreviated MRI","no contrast enhanced MRI","RECRUITING","2025-09-17",{"date":66,"type":34},"2025-09-22",{"date":68,"type":34},"2025-05-01",{"date":70,"type":20},"2039-04-30",{"name":72,"class":41},"University of Oxford",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100582683","optimized-remission-in-alcohol-related-liver-cirrhosis-100582683","NCT06866496","Optimized Remission in Alcohol-related Liver Cirrhosis","Disease and Outcomes in Alcohol Related Liver Cirrhosis - A Prospective Cohort Study of Optimized Remission","Pro-ALC","Inclusion Criteria:\n\n* Clinical suspicion of cirrhosis related to use of alcohol, supported by biochemistry and ultrasound or other imaging techniques.\n* Informed written consent.\n\nExclusion Criteria:\n\n* The diagnosis of ALC is questioned with reasonable doubt.\n* Withdrawal of informed consent or no informed consent.",{"count":83,"type":20},350,"INTERVENTIONAL",[86],"NA","The incidence of liver cirrhosis is increased fivefold for men and tripled for women in the last forty years.\n\nThe clinical course of liver cirrhosis includes complications of ascites, hepatic encephalopathy, variceal bleeding, kidney dysfunction, and infections that markedly worsen prognosis. These complications are driven by the development of portal hypertension in the liver. This progression to the 'decompensated' stage is considered a hallmark in the disease course, as the decompensation is associated with a markedly increased risk of further complications and death.\n\nIncreasing evidence indicate that active measures of treatment of the underlying cause of liver disease and removal of the toxic agents causing cirrhosis may slow disease progression or even induce regression of cirrhosis. This concept is described as hepatic recompensation.\n\nThere is a need for clinical studies investigating novel biomarkers with the capability to predict and monitor improvement in alcohol related liver cirrhosis, Between 75% and 80% of patients with liver cirrhosis in Denmark have or have had a harmful use of alcohol.\n\nAlcohol related liver disease (ArLD) has a major impact on patients' health and lives, and there is an unmet need to investigate treatment options that not only relieves complications, but also address the underlying pathways of alcohol related liver disease, also in severe stages of alcohol related cirrhosis (ALC). Factors such as BMI, female gender and mild portal hypertension are known to be associated with an increased likelihood of recompensation. Additional factors of genetic activation and molecular biomarkers from the proteome and lipidome have only attracted minor attention, and the impact of treating the drivers of decompensation, portal hypertension and alcohol use, and their impact on the natural cause of disease, have not been addressed.\n\nThe molecular pathophysiology of ArLD is incompletely understood. Characterization of the proteome dynamics across the spectrum of ALD could provide new insights into disease mechanisms of both progression and remission of disease.\n\nSeveral markers of inflammation and cytokines are involved in driving decompensation and has the potential to predict the risk of early death. It is unknown whether such markers can predict remission and recompensation in ALC and AH. Prospective studies investigating the associations between biomarkers of metabolism and prognosis, monitoring and efficacy og treatment in ALC are missing.\n\nThe overall objective of the present study is to investigate the molecular profile and pathways in persons with ALD to support personalized monitoring and follow-up in liver cirrhosis.\n\nThe study is an incidence cohort in which patients will be followed from diagnosis to death or withdrawal from the cohort. We will seek to include patients consecutively within three months of diagnosis.\n\nAll patients with a debut of alcohol related liver cirrhosis during admission regardless of the reason for admission, are eligible for inclusion.\n\nAll participants in this study will be offered the standard of care treatment. Alcohol cessation intervention including medical treatment of withdrawal symptoms and craving, referral to municipal offers of alcohol treatment, and motivational interviews is part of the treatment.\n\nThe study will contribute to a better characterization of advanced liver disease related to alcohol and contribute to an improved future organization of treatment- and rehabilitation offers to patients with liver disease. thorough characterization and consecutive inclusion will enhance our understanding on the incidence, prevalence and impact of ALC in the population, as well as the utilization of health care resources allocated to its treatment.\n\nA deeper insight into the molecular mechanisms of liver progression and remission will, in combination with clinical data, support our ability to predict outcomes in cirrhosis, facilitate personalized monitoring aiming at providing the right treatment for the right patient at the right time.",[24,89],"Alcoholic Cirrhosis",[91,92],"cirrhosis","ArLD","2025-03-05",{"date":95,"type":34},"2025-03-10",{"date":97,"type":34},"2024-12-22",{"date":99,"type":20},"2034-12-31",{"name":101,"class":41},"Copenhagen University Hospital, Hvidovre",1]